• Overview
  • Eligibility
  • More info
  • Locations

Drospirenone and Ethinyl Estradiol Combinations (Yasmin) as Infertility Treatments for Premature Ovarian Failure: a Perspective Follow-up Study. (NCT02757469)

Premature ovarian insufficiency (POI) is a life-changing condition that affects women in their reproductive age. There is a lack of reports which focus on how to improve the reproductive outcome of these women who wish to conceive spontaneously or use assisted conception with their own oocytes. However, one could surmise that it is important to lower gonadotropin levels into the physiological range before embarking on any treatment, even if natural conception is the only choice for the woman/couple.
  • Drug: Drospirenone and ethinyl estradiol combination (Yasmin)
    Female oral combined contraceptive containing 30 mcg (0.030 mg) Ethinyl Estradiol and 3 mg drospirenone (Androstenes)
    Ages eligible for Study
    18 Years to 40 Years
    Genders eligible for Study
    Female
    Accepts Healthy Volunteers
    No
    Inclusion Criteria:
    • premature ovarian failure
    • normal anatomy
    • normal secondary sexual characteristics
    • essential or idiopathic
    Exclusion Criteria:
    • chromosomal disorder
    • iatrogenic injury
    • autoimmune diseases
    • infection
    • genetic diseases

    1 locations

    China (1)
    • Navy General Hospital
      not yet recruiting
      Beijing, Beijing, China, 100048
    Status:
    unknown
    Type:
    Interventional
    Phase:
    -
    Start:
    30 April, 2016
    Updated:
    26 April, 2016
    Participants:
    20
    A girl giving information about available additional trials.

    FindMeCure helps you find, understand and join clinical trials from all over the world.

    There are more clinical trials for your condition!